

## AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A formulation comprising oxcarbazepine and an antidepressant, wherein said antidepressant is selected from the group consisting of bupropion and bupropion metabolites.
2. (Original) The formulation of Claim 1, further comprising a third drug selected from the group consisting of serotonin reuptake inhibitors, monoamine oxidase inhibitors, antipsychotic drugs, antianxiety/anxiolytic drugs, barbituates, stimulants, antiparkinsonian drugs, analgesic drugs, cardiac agents and nutraceuticals.
3. (Original) The formulation of Claim 1, wherein the form of said formulation is selected from the group consisting of a tablet, capsule, oral liquid, intrapulmonary liquid, transdermal patch, a polymer-coated tablet, a microparticle, a nanoparticle, an aerosol, fast-dissolve compound and a sterile injectable solution.
4. (Withdrawn) A method of treatment, comprising:
  - a) providing a patient exhibiting at least one symptom of a nervous system disorder, and
  - b) administering to the patient a formulation comprising oxcarbazepine and bupropion such that at least one symptom of said nervous system disorder is reduced.
5. (Withdrawn) The method of Claim 4, wherein said nervous system disorder is selected from the group consisting of childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders, eating disorders, sleep disorders, impulse-control disorders, adjustment disorders or personality disorders.

6. (Withdrawn) The formulation of Claim 4, further comprising a third drug selected from the group consisting of selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, antipsychotic drugs, antianxiety/anxiolytic drugs, barbiturates, stimulants, antiparkinsonian drugs, analgesic drugs, cardiac agents and nutraceuticals.

7. (Withdrawn) The method of Claim 4, wherein said formulation comprises a compounded formulation.

8. (Withdrawn) The method of Claim 7, wherein said compounded formulation further comprises said third drug.

9. (Withdrawn) A method of treatment, comprising:

- a) providing a patient exhibiting at least one symptom of a nervous system disorder and is being treated with a dose of a third drug, wherein said patient is non-remissive; and
- b) administering to said patient a formulation comprising a dose of oxcarbazepine and a dose of bupropion such that at least one symptom of said nervous system disorder is reduced.

10. (Withdrawn) The method of Claim 9, wherein said formulation further comprises said third drug.

11. (Withdrawn) The method of Claim 9, further comprising step (c), decreasing said dose of said third drug.

12. (Withdrawn) The method of Claim 9, wherein said administering of step (b) is performed over a period of time such that said dose of oxcarbazepine and said bupropion is increased.

13. (Withdrawn) The method of Claim 9, wherein said nervous system disorder is selected from the group comprising childhood disorders, cognitive disorders, substance

disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders, eating disorders, sleep disorders, impulse-control disorders, adjustment disorders or personality disorders..

14. (Withdrawn) The method of Claim 9, wherein said drug is selected from the group comprising selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, antipsychotic drugs, antianxiety/anxiolytic drugs, barbiturates, stimulants, antiparkinsonian drugs, analgesic drugs, cardiac agents and nutraceuticals.

15. (Withdrawn) The method of Claim 9, wherein said formulation comprises a compounded formulation.

16. (Withdrawn) The method of Claim 15, wherein said compounded formulation comprises said third drug.